|
1
|
Leonard JP, Williams ME, Goy A, Grant S,
Pfreundschuh M, Rosen ST and Sweetenham JW: Mantle cell lymphoma:
Biological insights and treatment advances. Clin Lymphoma Myeloma.
9:267–277. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertero M, Novelli M, Fierro MT and
Bernengo MG: Mantle zone lymphoma: An immunohistologic study of
skin lesions. J Am Acad Dermatol. 30:23–30. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weigert O, Unterhalt M, Hiddemann W and
Dreyling M: Mantle cell lymphoma: State-of-the-art management and
future perspective. Leuk Lymphoma. 50:1937–1950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Samaha H, Dumontet C, Ketterer N, Moullet
I, Thieblemont C, Bouafia F, Callet-Bauchu E, Felman P, Berger F,
Salles G and Coiffier B: Mantle cell lymphoma: A retrospective
study of 121 cases. Leukemia. 12:1281–1287. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oinonen R, Franssila K, Teerenhovi L,
Lappalainen K and Elonen E: Mantle cell lymphoma: Clinical
features, treatment and prognosis of 94 patients. Eur J Cancer.
34:329–336. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meusers P, Hense J and Brittinger G:
Mantle cell lymphoma: Diagnostic criteria, clinical aspects and
therapeutic problems. Leukemia. 11(Suppl 2): S60–S64.
1997.PubMed/NCBI
|
|
7
|
Howard OM, Gribben JG, Neuberg DS,
Grossbard M, Poor C, Janicek MJ and Shipp MA: Rituximab and CHOP
induction therapy for newly diagnosed mantle-cell lymphoma:
Molecular complete responses are not predictive of progression-free
survival. J Clin Oncol. 20:1288–1294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lenz G, Dreyling M, Hoster E, Wörmann B,
Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H,
Steinhauer H, et al: Immunochemotherapy with rituximab and
cyclophosphamide, doxorubicin, vincristine and prednisone
significantly improves response and time to treatment failure, but
not long-term outcome in patients with previously untreated mantle
cell lymphoma: Results of a prospective randomized trial of the
German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol.
23:1984–1992. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Argatoff LH, Connors JM, Klasa RJ, Horsman
DE and Gascoyne RD: Mantle cell lymphoma: A clinicopathologic study
of 80 cases. Blood. 89:2067–2078. 1997.PubMed/NCBI
|
|
10
|
Xu W and Li JY: SOX11 expression in mantle
cell lymphoma. Leuk Lymphoma. 51:1962–1967. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nygren L, Wennerholm Baumgartner S,
Klimkowska M, Christensson B, Kimby E and Sander B: Prognostic role
of SOX11 in a population-based cohort of mantle cell lymphoma.
Blood. 119:4215–4223. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernàndez V, Salamero O, Espinet B, Solé
F, Royo C, Navarro A, Camacho F, Beà S, Hartmann E, Amador V, et
al: Genomic and gene expression profiling defines indolent forms of
mantle cell lymphoma. Cancer Res. 70:1408–1418. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Geerts ML and Busschots AM: Mantle-cell
lymphomas of the skin. Dermatol Clin. 12:409–417. 1994.PubMed/NCBI
|
|
14
|
Martí RM, Campo E, Bosch F, Palou J and
Estrach T: Cutaneous lymphocyte-associated antigen (CLA) expression
in a lymphoblastoid mantle cell lymphoma presenting with skin
lesions. Comparison with other clinicopathologic presentations of
mantle cell lymphoma. J Cutan Pathol. 28:256–264. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moody BR, Bartlett NL, George DW, Price
CR, Breer WA, Rothschild Y and Kraus MD: Cyclin D1 as an aid in the
diagnosis of mantle cell lymphoma in skin biopsies: A case report.
Am J Dermatopathol. 23:470–476. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sen F, Medeiros LJ, Lu D, Jones D, Lai R,
Katz R and Abruzzo LV: Mantle cell lymphoma involving skin:
Cutaneous lesions may be the first manifestation of disease and
tumors often have blastoid cytologic features. Am J Surg Pathol.
26:1312–1318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dubus P, Young P, Beylot-Barry M,
Belaud-Rotureau MA, Courville P, Vergier B, Parrens M, Lenormand B,
Joly P and Merlio JP: Value of interphase FISH for the diagnosis of
t(11:14)(q13;q32) on skin lesions of mantle cell lymphoma. Am J
Clin Pathol. 118:832–841. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Motegi S, Okada E, Nagai Y, Tamura A and
Ishikawa O: Skin manifestation of mantle cell lymphoma. Eur J
Dermatol. 16:435–478. 2006.PubMed/NCBI
|
|
19
|
Estrozi B, Sanches JA Jr, Varela PC and
Bacchi CE: Primary cutaneous blastoid mantle cell lymphoma-case
report. Am J Dermatopathol. 31:398–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishibashi M, Yamamoto K, Kudo S and Chen
KR: Mantle cell lymphoma with skin invasion characterized by the
common variant in the subcutis and blastoid transformation in the
overlying dermis. Am J Dermatopathol. 32:180–182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Canpolat F, Taş E, Albayrak Sönmez A,
Oktay M, Eskioğlu F and Alper M: Cutaneous presentation of mantle
cell lymphoma. Acta Derm Venerol. 90:548–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zattra E, Zambello R, Marino F, Bordignon
M and Alaibac M: Primary cutaneous mantle cell lymphoma. Acta Derm
Venerol. 91:474–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lynch DW, Verma R, Larson E, Geis MC and
Jassim AD: Primary cutaneous mantle cell lymphoma with blastic
features: report of a rare case with special reference to staging
and effectiveness of chemotherapy. J Cutan Pathol. 39:449–453.
2012. View Article : Google Scholar : PubMed/NCBI
|
